Pittman Scott M. - 29 May 2026 Form 4 Insider Report for Nuo Therapeutics, Inc. (AURX)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: AURX
Reported as of: 29 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jun 2026, 21:54:30 UTC
Prior SEC filing: 02 Jun 2026
Next SEC filing: 02 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ David Jorden, attorney-in-fact

Key filing fact

Pittman Scott M. filed Form 4 for Nuo Therapeutics, Inc. (AURX) on 02 Jun 2026.

Key facts

This page summarizes Pittman Scott M.'s Form 4 filing for Nuo Therapeutics, Inc. (AURX).
5 reported transactions and 5 derivative rows are listed below.
Accepted by SEC: 02 Jun 2026, 21:54.

Change

Previous filing in this sequence was filed on 02 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001674752 Primary reporting owner

Pittman Scott M.

Relationship: Director, 10%+ Owner
Address: C/O NUO THERAPEUTICS, INC., 8285 EL RIO, SUITE190, HOUSTON
Signature: /s/ David Jorden, attorney-in-fact
Signature date: 02 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AURX transaction Derivative

Interim Warrant (right to buy)

Award

Transaction value
Shares: +17,450
Change %
Price: $1.50^*
Shares after: 17,450
Date: 29 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,450
Exercise price: $1.50
Footnotes: F1, F2

AURX transaction Derivative

Second Warrant (right to buy)

Disposed to Issuer

Transaction value
Shares: -36,750
Change %: -100%
Price: $1.50^*
Shares after: 0
Date: 29 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 36,750
Exercise price: $1.50
Footnotes: F2, F3, F4

AURX transaction Derivative

Prepayment Warrant (right to buy)

Disposed to Issuer

Transaction value
Shares: -7,516
Change %: -100%
Price: $1.50^*
Shares after: 0
Date: 29 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,516
Exercise price: $1.50
Footnotes: F2, F5

AURX transaction Derivative

Second Restated Warrant (right to buy)

Award

Transaction value
Shares: +17,500
Change %
Price: $1.50^*
Shares after: 0
Date: 29 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,500
Exercise price: $1.50
Footnotes: F2, F4, F6

AURX transaction Derivative

Prepayment Restated Warrant (right to buy)

Award

Transaction value
Shares: +7,333
Change %
Price: $1.50^*
Shares after: 0
Date: 29 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,333
Exercise price: $1.50
Footnotes: F2, F5, F7, F8

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 8 footnotes

Footnote F1

Represents Origination Interim and Capital Interim Warrants.

Footnote F2

Transaction approved by Board of Directors of Issuer and Non-Employee Directors

Footnote F3

Represents Origination Restated Second and Capital Restated Second Warrants.

Footnote F4

Previously issued Second Warrants cancelled for Second Restated Warrants with same terms, including same exercise price (and cancelled on date when underlying Common Stock traded at lower price than when previously issued), in accordance with the Amended and Restated Loan and Security Agreement dated May 29, 2026 among the Issuer, the Reporting Person, and other parties thereto (the "Loan Agreement").

Footnote F5

Previously issued Prepayment Warrants cancelled for Prepayment Restated Warrants with same terms, including same exercise price (and cancelled on date when underlying Common Stock traded at lower price than when previously issued), in accordance with the Loan Agreement.

Footnote F6

Vesting (if at all) on September 30, 2026 provided a Second Funding occurs in accordance with the Loan Agreement.

Footnote F7

Represents maximum number of shares issuable (if at all) in the event of a Prepayment in accordance with the Loan Agreement.

Footnote F8

Vesting (if at all) upon the occurrence of a Prepayment, but no later than December 31, 2028, in accordance with the Loan Agreement.